Citation: | XUE Jing, GUO Bo, HU Ling, FU Xing. Study on molecular mechanism of microRNA-203b-3p in regulating proliferation, migration and invasion of multiple myeloma cells[J]. Journal of Clinical Medicine in Practice, 2023, 27(15): 14-19, 23. DOI: 10.7619/jcmp.20230839 |
To observe the effect of microRNA-203b-3p (miR-203b-3p) on multiple myeloma (MM) cells by regulating tumor necrosis factor superfamily member 13b (TNFSF13B) and explore the related mechanism of miR-203b-3p in inhibiting MM.
Real-time fluorescent quantitative polymerase chain reaction (qRT-PCR) and Western blot were used to detect the expressions of miR-203b-3p and TNFSF13B in MM tumors and cells. The relationship between miR-203b-3p and TNFSF13B was validated by dual luciferase reporter experiments. Lipofectamine 2000 reagent was used for transfection of MM cells. The effects of miR-203b-3p and TNFSF13B on the biological function of MM cells were analyzed by colony formation assay, scratch assay, and Transwell assay.
Compared with the cancer-adjacent tissues and normal cells, the expressions of miR-203b-3p in MM tissues and cells were relatively low, while the expression of TNFSF13B in MM tumors and cells was increased when compared with normal tissues and cells, and the differences were statistically significant (P < 0.05). The dual luciferase reporter experiment showed that TNFSF13B was the direct target of miR-203b-3p. Overexpression of miR-203b-3p in MM cells was able to inhibit cell proliferation and migration, while upregulation of TNFSF13B promoted MM cell proliferation, migration and invasion(P < 0.05).
MiR-203b-3p may inhibit the proliferation, invasion and migration of MM cells by downregulating TNFSF13B.
[1] |
HASHEMI M, ROSHANZAMIR S M, PASKEH M D A, et al. Non-coding RNAs and exosomal ncRNAs in multiple myeloma: an emphasis on molecular pathways[J]. Eur J Pharmacol, 2023, 941: 175380. doi: 10.1016/j.ejphar.2022.175380
|
[2] |
WEI X J, YU Z, TANG P X, et al. Multiple myeloma-derived miR-27b-3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment[J]. Clin Transl Med, 2023, 13(1): e1140. doi: 10.1002/ctm2.1140
|
[3] |
ROY P, MUKHERJEE T, CHATTERJEE B, et al. Non-canonical NFκB mutations reinforce pro-survival TNF response in multiple myeloma through an autoregulatory RelB: p50 NFκB pathway[J]. Oncogene, 2017, 36(10): 1417-1429. doi: 10.1038/onc.2016.309
|
[4] |
GÖRGÜN G, SAMUR M K, COWENS K B, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma[J]. Clin Cancer Res, 2015, 21(20): 4607-4618. doi: 10.1158/1078-0432.CCR-15-0200
|
[5] |
HILL M, TRAN N. miRNA interplay: mechanisms and consequences in cancer[J]. Dis Model Mech, 2021, 14(4): dmm047662. doi: 10.1242/dmm.047662
|
[6] |
SENGUPTA D, DEB M, KAR S, et al. Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention[J]. Semin Cancer Biol, 2021, 72: 46-64. doi: 10.1016/j.semcancer.2020.05.017
|
[7] |
ZHANG M L, BAI X, ZENG X M, et al. circRNA-miRNA-mRNA in breast cancer[J]. Clin Chim Acta, 2021, 523: 120-130. doi: 10.1016/j.cca.2021.09.013
|
[8] |
HUANG X J, ZHU X P, YU Y, et al. Dissecting miRNA signature in colorectal cancer progression and metastasis[J]. Cancer Lett, 2021, 501: 66-82. doi: 10.1016/j.canlet.2020.12.025
|
[9] |
PAN G T, LIU Y H, SHANG L R, et al. EMT-associated microRNAs and their roles in cancer stemness and drug resistance[J]. Cancer Commun, 2021, 41(3): 199-217. doi: 10.1002/cac2.12138
|
[10] |
SABIT H, CEVIK E, TOMBULOGLU H, et al. Triple negative breast cancer in the era of miRNA[J]. Crit Rev Oncol Hematol, 2021, 157: 103196. doi: 10.1016/j.critrevonc.2020.103196
|
[11] |
ZHAO Y, XIE Z S, LIN J, et al. miR-144-3p inhibits cell proliferation and induces apoptosis in multiple myeloma by targeting c-Met[J]. Am J Transl Res, 2017, 9(5): 2437-2446.
|
[12] |
WU S Q, NIU W Y, LI Y P, et al. miR-203 inhibits cell growth and regulates G1/S transition by targeting Bmi-1 in myeloma cells[J]. Mol Med Rep, 2016, 14(5): 4795-4801. doi: 10.3892/mmr.2016.5832
|
[13] |
AAKKO S, STRAUME A H, BIRKELAND E E, et al. MYC-induced miR-203b-3p and miR-203a-3p control bcl-xL expression and paclitaxel sensitivity in tumor cells[J]. Transl Oncol, 2019, 12(1): 170-179. doi: 10.1016/j.tranon.2018.10.001
|
[14] |
GAO L P, MORINE Y, YAMADA S, et al. The BAFF/NFκB axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts[J]. Cancer Sci, 2021, 112(9): 3545-3554. doi: 10.1111/cas.15041
|
[15] |
MA T M, MENG L F, WANG X N, et al. TNFSF13B and PPARGC1A expression is associated with tumor-infiltrating immune cell abundance and prognosis in clear cell renal cell carcinoma[J]. Am J Transl Res, 2021, 13(10): 11048-11064.
|
[16] |
SCHWEIGHOFFER E, TYBULEWICZ V L. BAFF signaling in health and disease[J]. Curr Opin Immunol, 2021, 71: 124-131. doi: 10.1016/j.coi.2021.06.014
|
[17] |
LI Y C, XIE X P, JIE Z L, et al. DYRK1a mediates BAFF-induced noncanonical NF-κB activation to promote autoimmunity and B-cell leukemogenesis[J]. Blood, 2021, 138(23): 2360-2371. doi: 10.1182/blood.2021011247
|
[18] |
DI LEVA G, GAROFALO M, CROCE C M. microRNAs in cancer[J]. Annu Rev Pathol, 2014, 9: 287-314. doi: 10.1146/annurev-pathol-012513-104715
|
[19] |
LEONE E, MORELLI E, DI MARTINO M T, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth[J]. Clin Cancer Res, 2013, 19(8): 2096-2106. doi: 10.1158/1078-0432.CCR-12-3325
|
[20] |
YANG Y J, LI F, SAHA M N, et al. miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma[J]. Clin Cancer Res, 2015, 21(10): 2399-2411. doi: 10.1158/1078-0432.CCR-14-1437
|
[21] |
ALUVILA S, SUN J K, HARRISON D H, et al. Inhibitors of the mitochondrial citrate transport protein: validation of the role of substrate binding residues and discovery of the first purely competitive inhibitor[J]. Mol Pharmacol, 2010, 77(1): 26-34. doi: 10.1124/mol.109.058750
|
[22] |
ZHANG C Y, LIU P, HUANG J M, et al. Circular RNA hsa_circ_0043280 inhibits cervical cancer tumor growth and metastasis via miR-203a-3p/PAQR3 axis[J]. Cell Death Dis, 2021, 12(10): 888. doi: 10.1038/s41419-021-04193-7
|
[23] |
AN N, ZHENG B. miR-203a-3p inhibits pancreatic cancer cell proliferation, EMT, and apoptosis by regulating SLUG[J]. Technol Cancer Res Treat, 2020, 19: 1533033819898729.
|
[24] |
YANG P S, ZHANG D D, ZHOU F L, et al. miR-203a-3p-DNMT3B feedback loop facilitates non-small cell lung cancer progression[J]. Hum Cell, 2022, 35(4): 1219-1233. doi: 10.1007/s13577-022-00728-y
|
[25] |
MAGIERA M M, GUEYDON E, SCHWOB E. DNA replication and spindle checkpoints cooperate during S phase to delay mitosis and preserve genome integrity[J]. J Cell Biol, 2014, 204(2): 165-175. doi: 10.1083/jcb.201306023
|
[26] |
BRUNETTI G, RIZZI R, STORLINO G, et al. LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens[J]. Front Immunol, 2018, 9: 2459. doi: 10.3389/fimmu.2018.02459
|
[27] |
ZHU X J, SHI Y, ZHANG F, et al. Reduced tumour necrosis factor receptor superfamily 13C inversely correlated with tumour necrosis factor superfamily 13B in patients with immune thrombocytopenia[J]. Br J Haematol, 2014, 166(5): 783-791. doi: 10.1111/bjh.12958
|
[28] |
PENZA V, MAROUN J W, NACE R A, et al. Polycytidine tract deletion from microRNA-detargeted oncolytic Mengovirus optimizes the therapeutic index in a murine multiple myeloma model[J]. Mol Ther Oncolytics, 2023, 28: 15-30. doi: 10.1016/j.omto.2022.11.006
|